# OnCo record gastric-cancer-signalling (pathway). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/pathways/gastric-cancer-signalling/>
  a schema:BioChemEntity ;
  onco:kind "pathway" ;
  schema:identifier "gastric-cancer-signalling" ;
  schema:name "Gastric cancer (KEGG map)"@en ;
  schema:alternateName "KEGG hsa05226"@en, "Gastric cancer"@en ;
  schema:description "This KEGG map splits stomach cancer into two routes: the intestinal type that accumulates TP53, APC and HER2 changes step by step, and the diffuse type driven by loss of the cell glue E-cadherin plus MET or FGFR2 amplification. It matters because HER2, FGFR2, claudin 18.2 and PD-1 status now decide first-line treatment."@en ;
  schema:url <https://onco.cc/pathways/gastric-cancer-signalling/> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:citation <https://www.kegg.jp/pathway/hsa05226>, <https://doi.org/10.1016/S0140-6736(20)31288-5> ;
  onco:related <https://onco.cc/pathways/rtk-activation/>, <https://onco.cc/pathways/fgfr-signalling/>, <https://onco.cc/pathways/emt/>, <https://onco.cc/pathways/pd1-checkpoint/> ;
  onco:cancers <https://onco.cc/cancers/gastric/> ;
  onco:targets <https://onco.cc/targets/tp53/>, <https://onco.cc/targets/her2/>, <https://onco.cc/targets/fgfr2/>, <https://onco.cc/targets/met/>, <https://onco.cc/targets/kras/>, <https://onco.cc/targets/pik3ca/>, <https://onco.cc/targets/cldn18-2/>, <https://onco.cc/targets/pd1/>, <https://onco.cc/targets/vegf/> ;
  onco:drugs <https://onco.cc/drugs/trastuzumab/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/trastuzumab-deruxtecan/>, <https://onco.cc/drugs/zanidatamab/>, <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/drugs/zolbetuximab/>, <https://onco.cc/drugs/bemarituzumab/>, <https://onco.cc/drugs/ramucirumab/>, <https://onco.cc/drugs/paclitaxel/> ;
  onco:pathways <https://onco.cc/pathways/rtk-activation/>, <https://onco.cc/pathways/fgfr-signalling/>, <https://onco.cc/pathways/ras-mapk/>, <https://onco.cc/pathways/pi3k-akt-mtor/>, <https://onco.cc/pathways/p53-cell-cycle/>, <https://onco.cc/pathways/wnt/>, <https://onco.cc/pathways/tgf-beta/>, <https://onco.cc/pathways/emt/>, <https://onco.cc/pathways/pd1-checkpoint/>, <https://onco.cc/pathways/mismatch-repair-msi/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-smyth-lancet/> .